Assembly Biosciences Announces Quarterly Results for June 30, 2026

What Happened
Assembly Biosciences, Inc. announced financial results for the quarter ended June 30, 2026 via a press release issued on August 13, 2026. The company filed an 8-K on August 14, 2026 (Item 2.02) furnishing that press release as Exhibit 99.1. The filing was signed by John O. Gunderson, VP, General Counsel and Corporate Secretary.

Key Details

• Press release announcing quarterly results was issued on August 13, 2026 and attached to the 8-K as Exhibit 99.1.
• The results cover the quarter ended June 30, 2026 (quarterly results / earnings period).
• 8-K was filed with the SEC on August 14, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• Filing executed by John O. Gunderson (VP, General Counsel and Corporate Secretary).

Why It Matters
This 8-K notifies investors that Assembly has publicly disclosed its latest quarterly results (earnings, revenue and related financial information) via a press release. The 8-K itself furnishes the press release but does not restate financial details — investors should read Exhibit 99.1 (the press release) for specific figures (revenue, net income/loss, cash position, guidance or operational updates) that could affect valuation or near-term trading.